Long-term effects of carboplatin brainstem infusions on hearing thresholds in monkeys

Archives of Otolaryngology - Head and Neck Surgery

Volumn 130, Issue 12, 2004, Pages 1411-1415

  May, Bradford J ^a   Guarnieri, Michael ^a   Carson Sr , Benjamin S ^a   Bachani, Abdul ^a   Jallo, George I ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN;

ADOLESCENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUDITORY NERVOUS SYSTEM; AUDITORY THRESHOLD; BRAIN CANCER; BRAIN STEM; CANCER CHEMOTHERAPY; COCHLEA; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG EFFECT; DRUG INFUSION; EVOKED BRAIN STEM AUDITORY RESPONSE; HAIR CELL; HEARING IMPAIRMENT; LONG TERM EFFECT; MACACA; MALE; MONKEY; NEUROTOXICITY; NONHUMAN; OTOTOXICITY;

ANIMALS; ANTINEOPLASTIC AGENTS; AUDITORY PATHWAYS; AUDITORY THRESHOLD; BRAIN STEM; CARBOPLATIN; DRUG DELIVERY SYSTEMS; HEARING; INFUSIONS, INTRALESIONAL; MACACA FASCICULARIS; MALE;

EID: 10044240443     PISSN: 08864470     EISSN: None     Source Type: Journal    
DOI: 10.1001/archotol.130.12.1411     Document Type: Article

References (20)

1. Reed E. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev. 1998;24:331-344.
2. Wagstaff AJ, Ward A, Benfield P, Heel RC. Carboplatin: a preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of cancer. Drugs. 1989;37:162-190.
3. Simon T, Hero B, Dupuis W, Selle B, Berthold F. The incidence of hearing impairment after successful treatment of neuroblastoma. Klin Padiatr. 2002;214: 149-152.
4. Henderson D, Hu B, McFadden S, Zheng X. Evidence of a common pathway in noise-induced hearing loss and carboplatin ototoxicity. Noise Health. 1999; 2:53-70.
5. Macdonald MR, Harrison RV, Wake M, Bliss B, Macdonald RE. Ototoxicity of carboplatin: comparing animal and clinical models at the Hospital for Sick Children. J Otolaryngol. 1994;23:151-159.
6. Husain K, Whitworth C, Hazelrigg S, Rybak L. Carboplatin-induced oxidative injury in rat inferior colliculus. Int J Toxicol. 2003;22:335-342.
7. Williams PC, Henner WD, Roman-Goldstein S, et al. Toxicity and efficacy of carboplatin and etoposide in conjunction with disruption of the blood-brain tumor barrier in the treatment of intracranial neoplasms. Neurosurgery. 1995;37:17-27.
8. Blakley BW, Cohen JI, Doolittle ND, et al. Strategies for prevention of toxicity caused by platinum-based chemotherapy: review and summary of the annual meeting of the Blood-Brain Barrier Disruption Program, Gleneden Beach, Oregon, March 10, 2001. Laryngoscope. 2002;112:1997-2001.
9. Storm PB, Clatterbuck RE, Liu YJ, et al. A surgical technique for safely placing a drug delivery catheter into the pons of primates: preliminary results of carboplatin infusion. Neurosurgery. 2003;52:1169-1176.
10. Strege RJ, Liu YJ, Kiely A, et al. Toxicity and cerebrospinal fluid levels of carboplatin chronically infused into the brainstem of a primate. J Neurooncol. 2004; 67:327-334.
11. Ngan EM, May BJ. Relationship between the auditory brainstem response and auditory nerve thresholds in cats with hearing loss. Hear Res. 2001;156:44-52.
12. Guarnieri M, Biser-Rohrbaugh A, Tyler BM, et al. Toxicity of intracranial and intraperitoneal 06-benzyl guanine in combination with BCNU delivered locally in a mouse model. Cancer Chemother Pharmacol. 2002;50:392-396.
13. Carson BS Sr, Wu QZ, Tyler BM. New approach to tumor therapy for inoperable areas of the brain: chronic intraparenchymal drug delivery. J Neurooncol. 2002; 60:151-158.
14. Wenig BL, Werner JA, Castro DJ, et al. The role of intratumoral therapy with cisplatin/epinephrine injectable gel in the management of advanced squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 2002;128: 880-885.
15. Friberg G, Fleming G. Intraperitoneal chemotherapy for ovarian cancer. Curr Oncol Rep. 2003;5:447-453.
16. Brem H, Piantadosi S, Burger PC, et al; The Polymer-brain Tumor Treatment Group. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet. 1995;345:1008-1012.
17. Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-oncol. 2003;5:79-88.
18. Wimmer C, Mees K, Stumpf P, Welsch U, Reichel O, Suckfull M. Round window application of D-methionine, sodium thiosulfate, brain-derived neurotrophic factor, and fibroblast growth factor-2 in cisplatin-induced ototoxicity. Otol Neurotol. 2004;25:33-40.
19. Achor LJ, Starr A. Auditory brain stem responses in the cat: intracranial and extracranial recordings. Electroencephalogr Clin Neurophysiol. 1980;48:154-173.
20. Wada SI, Starr A. Generation of auditory brain stem responses (ABRs), III: effects of lesions of the superior olive, lateral lemniscus and inferior colliculus on the ABR in guinea pig. Bectroencephalogr Clin Neurophysiol. 1983;56:352-366.